

Performance in Delivering QTR 4 Jan- March 2019

| Research Ethics Committee Reference Number | Integrated Research Application System Number | Name of Trial | Target Number Of Patients Agreed? | Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number) | Target Date To Recruit Patients Agreed? | Date Agreed to recruit target number of patients | Total Number Of Patients Recruited At The Agreed Target Date | Date That The Trial Closed To Recruitment | Total Number Of Study Participants Recruited | Reason For Closure Of Trial | Comments |
|--|---|---|-----------------------------------|---|---|---|--|--|---|--|-----------------------------|--|
| 16/EM/0194 | 194984 | DERM 5311 Effectiveness of an image analysing algorithm to diagnose melanoma compared to gold standard histological determination | Number Agreed | 23 | 23 | Date Agreed | 30/09/2018 | 23 | 29/06/2018 | 23 | Recruitment Finished | Recruitment was originally extended from 31/05/18 to 30/09/18, however Sponsor closed recruitment 29/06/18 |
| 17/LO/0794 | 223700 | RHCF - A 52-week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive | Number Agreed | 2 | 2 | Date Agreed | 30/04/2018 | 2 | 30/04/2018 | 2 | Recruitment Finished | |
| 17/LO/1147 | 222154 | EC2TRA 2 - Tralokinumab in moderate-severe AD -1326 | Number Agreed | 6 | 6 | Date Agreed | 31/05/2018 | 7 | 26/04/2018 | 7 | Recruitment Finished | Due to study recruitment numbers being met earlier |
| 16/EM/0384 | 182787 | BMS Augustus - "An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Aplixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and ACS or PCI | Number Agreed | 6 | 6 | Date Agreed | 31/05/2018 | 1 | 10/04/2018 | 1 | Recruitment Finished | Due to study recruitment numbers being met earlier |
| 17/EE/0079 | 220827 | CI010_168 A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in pts with anti-neutrophil cytoplasmic antibody (ANCA)- Associated Vasculitis | Number Agreed | 2 | 2 | Date Agreed | 31/12/2018 | 0 | 04/07/2018 | 0 | Recruitment Finished | Due to study recruitment numbers being met earlier |
| 18/YH/0012 | 237184 | EC2TRA 3 (ECZema TRAlokinumab trial no. 3) | Number Agreed | 6 | 6 | Date Agreed | 18/08/2018 | 4 | 12/10/2018 | 4 | Recruitment Finished | PI taken long term sickness absence, which affected reaching recruitment target |
| 16/EM/0193 | 190690 | The Dal-GenE trial (CARD 4843) A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS) | Number Agreed | 6 | 6 | Date Agreed | 31/10/2018 | 7 | 12/11/2018 | 7 | Recruitment Finished | |
| 18/SC/0210 | 239572 | EFFICACY AND SAFETY OF PF-04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS WITH AD | Number Agreed | 1 | 1 | Date Agreed | 26/11/2018 | 0 | 26/11/2018 | 0 | Recruitment Finished | Difficult to recruit to |
| 16/LO/1822 | 212944 | VICTORIA - A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction | Number Agreed | 10 | 10 | Date Agreed | 31/12/2018 | 11 | 31/12/2018 | 11 | Recruitment Finished | |
| 16/WM/0365 | 210358 | A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics | Number Agreed | 2 | 2 | Date Agreed | 30/09/2018 | 4 | 31/01/2019 | 4 | Recruitment Finished | |